HC Wainwright Has Bullish Outlook for NovoCure Q2 Earnings

NovoCure Limited (NASDAQ:NVCR) – Research analysts at HC Wainwright boosted their Q2 2026 earnings estimates for shares of NovoCure in a note issued to investors on Thursday, July 23rd. HC Wainwright analyst E. Bodnar now anticipates that the medical equipment provider will post earnings of ($0.13) per share for the quarter, up from their previous estimate of ($0.23). The consensus estimate for NovoCure’s current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for NovoCure’s Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($1.05) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($0.37) EPS and FY2030 earnings at $4.53 EPS.

Several other equities research analysts have also weighed in on NVCR. Wedbush raised their target price on NovoCure from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Wells Fargo & Company upped their price target on NovoCure from $13.50 to $17.00 and gave the company an “equal weight” rating in a report on Monday, May 4th. Weiss Ratings raised NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 1st. JPMorgan Chase & Co. initiated coverage on shares of NovoCure in a research note on Monday, July 13th. They issued a “neutral” rating and a $17.00 price target on the stock. Finally, Zacks Research raised shares of NovoCure from a “strong sell” rating to a “hold” rating in a report on Friday, July 24th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $21.20.

NovoCure Stock Down 4.2%

Shares of NASDAQ NVCR opened at $16.31 on Monday. The business has a 50-day moving average of $16.62 and a two-hundred day moving average of $14.18. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -12.55 and a beta of 0.94. NovoCure has a 1 year low of $9.82 and a 1 year high of $21.45. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.89 and a quick ratio of 2.70.

NovoCure (NASDAQ:NVCR) last posted its earnings results on Thursday, July 23rd. The medical equipment provider reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.20. NovoCure had a negative return on equity of 44.00% and a negative net margin of 21.25%.The firm had revenue of $183.58 million for the quarter, compared to analyst estimates of $172.44 million. During the same quarter in the prior year, the company posted ($0.36) earnings per share. NovoCure’s revenue for the quarter was up 15.6% compared to the same quarter last year.

Insider Activity at NovoCure

In other NovoCure news, Director Jeryl L. Hilleman sold 2,945 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total transaction of $46,442.65. Following the transaction, the director owned 13,861 shares of the company’s stock, valued at approximately $218,587.97. This trade represents a 17.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Frank X. Leonard sold 34,273 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $17.93, for a total value of $614,514.89. Following the completion of the sale, the chief executive officer directly owned 459,520 shares of the company’s stock, valued at $8,239,193.60. The trade was a 6.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 51,943 shares of company stock valued at $893,171. Corporate insiders own 5.52% of the company’s stock.

Institutional Investors Weigh In On NovoCure

Large investors have recently modified their holdings of the company. Empowered Funds LLC acquired a new position in shares of NovoCure in the 4th quarter valued at $33,000. Kestra Advisory Services LLC acquired a new stake in NovoCure during the 4th quarter worth $49,000. Larson Financial Group LLC grew its position in NovoCure by 662.1% during the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 3,562 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in NovoCure by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock worth $70,000 after purchasing an additional 1,120 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new position in NovoCure during the 1st quarter worth $87,000. 84.61% of the stock is owned by institutional investors and hedge funds.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.